Who are MHOS/SHP615's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MACIMORELIN ACETATE, Macrilen, KW-6500, L-ARG+GHRH.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mhos-shp615.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

MHOS/SHP615 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MHOS/SHP615 (MHOS/SHP615) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth hormone secretagogue. Area: Endocrinology.

phase 3 Growth hormone secretagogue Ghrelin receptor (GHSR-1a) Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

MHOS/SHP615 (MHOS/SHP615) — Shire. MHOS/SHP615 is a long-acting growth hormone secretagogue (ghrelin receptor agonist) that stimulates growth hormone release.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MHOS/SHP615 TARGET	MHOS/SHP615	Shire	phase 3	Growth hormone secretagogue	Ghrelin receptor (GHSR-1a)
MACIMORELIN ACETATE	MACIMORELIN ACETATE		marketed	Growth Hormone Secretagogue Receptor Agonist [EPC]		2017-01-01
Macrilen	MACIMORELIN	Aeterna Zentaris	marketed	Growth Hormone Secretagogue Receptor Agonist	Growth hormone secretagogue receptor type 1	2017-01-01
KW-6500	KW-6500	Kyowa Kirin Co., Ltd.	phase 3	Growth hormone secretagogue	Ghrelin receptor (GHS-R1a)
L-ARG+GHRH	L-ARG+GHRH	AEterna Zentaris	phase 3	Growth hormone secretagogue / amino acid combination	GHRH receptor (GHRHR); nitric oxide pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth hormone secretagogue class)

Kyowa Kirin Co., Ltd. · 1 drug in this class
Shire · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MHOS/SHP615 — Competitive Intelligence Brief. https://druglandscape.com/ci/mhos-shp615. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing